Nectar Lifesciences Limited (NECLIFE.NS)
INR 26.37
(-5.01%)
INR 26.37
(-5.01%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 11.21 Billion INR | -0.25% |
| 2022 | 11.24 Billion INR | -13.69% |
| 2021 | 13.02 Billion INR | -7.53% |
| 2020 | 14.09 Billion INR | -5.88% |
| 2019 | 14.97 Billion INR | -6.42% |
| 2018 | 15.99 Billion INR | -3.92% |
| 2017 | 16.65 Billion INR | 5.78% |
| 2016 | 15.74 Billion INR | -3.65% |
| 2015 | 16.33 Billion INR | 5.25% |
| 2014 | 15.52 Billion INR | 5.83% |
| 2013 | 14.67 Billion INR | 4.31% |
| 2012 | 14.06 Billion INR | 5.24% |
| 2011 | 13.36 Billion INR | 22.44% |
| 2010 | 10.91 Billion INR | 26.94% |
| 2009 | 8.59 Billion INR | -12.46% |
| 2008 | 9.82 Billion INR | 47.82% |
| 2007 | 6.64 Billion INR | 19.46% |
| 2006 | 5.56 Billion INR | 112.82% |
| 2005 | 2.61 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -10.69 Billion INR | -195.31% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 10.75 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 11.21 Billion INR | 0.0% |
| 2023 FY | 11.21 Billion INR | -0.25% |
| 2022 Q2 | 12.18 Billion INR | 0.0% |
| 2022 Q4 | 11.24 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 11.24 Billion INR | -13.69% |
| 2021 Q4 | 13.02 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 13.02 Billion INR | -7.53% |
| 2021 Q2 | 13.02 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 14.09 Billion INR | -5.88% |
| 2020 Q2 | 14.24 Billion INR | 0.0% |
| 2020 Q4 | 14.09 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q4 | 14.97 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 FY | 14.97 Billion INR | -6.42% |
| 2019 Q2 | 15.84 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2018 Q4 | 15.99 Billion INR | 0.0% |
| 2018 FY | 15.99 Billion INR | -3.92% |
| 2017 FY | 16.65 Billion INR | 5.78% |
| 2016 FY | 15.74 Billion INR | -3.65% |
| 2015 FY | 16.33 Billion INR | 5.25% |
| 2014 FY | 15.52 Billion INR | 5.83% |
| 2013 FY | 14.67 Billion INR | 4.31% |
| 2012 FY | 14.06 Billion INR | 5.24% |
| 2011 FY | 13.36 Billion INR | 22.44% |
| 2010 FY | 10.91 Billion INR | 26.94% |
| 2009 FY | 8.59 Billion INR | -12.46% |
| 2008 FY | 9.82 Billion INR | 47.82% |
| 2007 FY | 6.64 Billion INR | 19.46% |
| 2006 FY | 5.56 Billion INR | 112.82% |
| 2005 FY | 2.61 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | -551.386% |
| Aarti Drugs Limited | 11.5 Billion INR | 2.485% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | -35.965% |
| Ajanta Pharma Limited | 10.71 Billion INR | -4.741% |
| Alembic Limited | 1.43 Billion INR | -683.331% |
| Alkem Laboratories Limited | 48.6 Billion INR | 76.92% |
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 31.067% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -206.412% |
| Bal Pharma Limited | 2.51 Billion INR | -346.709% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -3784.392% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -431.952% |
| Brooks Laboratories Limited | 248.6 Million INR | -4412.486% |
| Bafna Pharmaceuticals Limited | 652.27 Million INR | -1619.829% |
| Caplin Point Laboratories Limited | 3.5 Billion INR | -220.005% |
| Divi's Laboratories Limited | 18.99 Billion INR | 40.926% |
| Eris Lifesciences Limited | 38.26 Billion INR | 70.686% |
| Granules India Limited | 22.95 Billion INR | 51.129% |
| Ind-Swift Limited | 13.45 Billion INR | 16.613% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -3680.188% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | -4.764% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 81.692% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -1642.255% |
| Medicamen Biotech Limited | 940.36 Million INR | -1092.948% |
| Medico Remedies Limited | 438.24 Million INR | -2459.781% |
| Wockhardt Limited | 39.87 Billion INR | 71.863% |
| Orchid Pharma Limited | 3.84 Billion INR | -191.828% |
| RPG Life Sciences Limited | 1.38 Billion INR | -712.787% |
| Shilpa Medicare Limited | 12.93 Billion INR | 13.256% |
| Sigachi Industries Limited | 2.53 Billion INR | -343.181% |
| Solara Active Pharma Sciences Limited | 14.09 Billion INR | 20.393% |
| Unichem Laboratories Limited | 8.06 Billion INR | -39.023% |
| Vaishali Pharma Limited | 371.16 Million INR | -2922.415% |
| Wanbury Limited | 3.15 Billion INR | -255.507% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 84.374% |
| FDC Limited | 3.7 Billion INR | -202.439% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -1331.199% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -130.461% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 89.513% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -116.528% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -389.988% |
| Laurus Labs Limited | 42.71 Billion INR | 73.737% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -467.628% |
| Par Drugs and Chemicals Limited | 159.79 Million INR | -6920.474% |
| Hester Biosciences Limited | 3.59 Billion INR | -212.071% |
| Ipca Laboratories Limited | 33.74 Billion INR | 66.754% |
| Venus Remedies Limited | 1.39 Billion INR | -705.434% |
| ZIM Laboratories Limited | 2.08 Billion INR | -439.134% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 92.63% |
| Morepen Laboratories Limited | 4.45 Billion INR | -151.538% |
| Neuland Laboratories Limited | 5.49 Billion INR | -104.019% |
| Sequent Scientific Limited | 8.27 Billion INR | -35.578% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -451.466% |
| Valiant Laboratories Limited | 1.05 Billion INR | -960.049% |
| Windlas Biotech Limited | 1.76 Billion INR | -536.415% |
| Hikal Limited | 12.99 Billion INR | 13.673% |
| Innova Captab Limited | 4.89 Billion INR | -128.947% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -338.001% |
| Themis Medicare Limited | 1.88 Billion INR | -494.332% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -77.252% |
| Mankind Pharma Limited | 23.87 Billion INR | 53.013% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 82.771% |
| Sakar Healthcare Limited | 1.26 Billion INR | -788.013% |
| Albert David Limited | 1.15 Billion INR | -875.397% |
| Lupin Limited | 96.23 Billion INR | 88.343% |
| Gufic Biosciences Limited | 5.59 Billion INR | -100.33% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 93.889% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -943.985% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -862.751% |
| Piramal Enterprises Limited | 560.47 Billion INR | 97.998% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 86.328% |
| NATCO Pharma Limited | 10.53 Billion INR | -6.514% |
| Suven Life Sciences Limited | 148.62 Million INR | -7448.116% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -277.216% |
| Strides Pharma Science Limited | 37.68 Billion INR | 70.228% |
| Indoco Remedies Limited | 10.34 Billion INR | -8.468% |
| Alpa Laboratories Limited | 307.12 Million INR | -3552.648% |
| Lasa Supergenerics Limited | 541.92 Million INR | -1970.044% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -188.168% |